Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

TL;DR

This study reveals that the drug abacavir binds to HLA-B*57:01, altering its peptide presentation and triggering immune responses, which explains the genetic basis of certain drug hypersensitivities.

Contribution

It demonstrates how abacavir modifies the self-peptide repertoire presented by HLA-B*57:01, providing a mechanistic explanation for HLA-linked drug hypersensitivity reactions.

Findings

Abacavir binds within the peptide-binding groove of HLA-B*57:01.

Altered peptide presentation triggers T cell responses in hypersensitive patients.

The assays developed can test other drugs for HLA-linked hypersensitivities.

Abstract

Idiosyncratic adverse drug reactions are unpredictable, dose independent and potentially life threatening; this makes them a major factor contributing to the cost and uncertainty of drug development. Clinical data suggest that many such reactions involve immune mechanisms, and genetic association studies have identified strong linkage between drug hypersensitivity reactions to several drugs and specific HLA alleles. One of the strongest such genetic associations found has been for the antiviral drug abacavir, which causes severe adverse reactions exclusively in patients expressing the HLA molecular variant B*57:01. Abacavir adverse reactions were recently shown to be driven by drug-specific activation of cytokine-producing, cytotoxic CD8+ T cells that required HLA-B*57:01 molecules for their function. However, the mechanism by which abacavir induces this pathologic T cell response remains unclear. Here we show that abacavir can bind within the F-pocket of the peptide-binding groove of HLA-B*57:01 thereby altering its specificity. This supports a novel explanation for HLA-linked idiosyncratic adverse drug reactions; namely that drugs can alter the repertoire of self-peptides presented to T cells thus causing the equivalent of an alloreactive T cell response. Indeed, we identified specific self-peptides that are presented only in the presence of abacavir, and that were recognized by T cells of hypersensitive patients. The assays we have established can be applied to test additional compounds with suspected HLA linked hypersensitivities in vitro. Where successful, these assays could speed up the discovery and mechanistic understanding of HLA linked hypersensitivities as well as guide the development of safer drugs.